Bioxytran, Inc (BIXT) stock
BIXTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.02−0.00 (-3.95%)
Close on Oct 19, 2026Market cap $2.56MP/E –Yield –
Bioxytran net income
Net income is the profit left for shareholders after every expense, interest and tax.
Bioxytran's net income for the twelve months ending Jun 30, 2026 was -$3.49M. For fiscal 2025 it was -$2.12M. The highest annual figure on record is -$296.42K in fiscal 2018.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.12M | – |
| FY2024 | Dec 31, 2024 | -$2.37M | – |
| FY2023 | Dec 31, 2023 | -$4.47M | – |
| FY2022 | Dec 31, 2022 | -$2.47M | – |
| FY2021 | Dec 31, 2021 | -$4.03M | – |
| FY2020 | Dec 31, 2020 | -$2.54M | – |
| FY2019 | Dec 31, 2019 | -$1.86M | – |
| FY2018 | Dec 31, 2018 | -$296.42K | – |
| FY2017 | Dec 31, 2017 | -$318.39K | – |
| FY2016 | Dec 31, 2016 | -$696.76K | – |
| FY2015 | Dec 31, 2015 | -$2.10M | – |
| FY2014 | Dec 31, 2014 | -$1.35M | – |
| FY2013 | Dec 31, 2013 | -$1.78M | – |
| FY2012 | Dec 31, 2012 | -$2.29M | – |
| FY2011 | Dec 31, 2011 | -$4.43M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$619.93K | -1849.3% |
| Q1 FY2026 | Mar 31, 2026 | -$2.07M | – |
| Q4 FY2025 | Dec 31, 2025 | -$522.16K | – |
| Q3 FY2025 | Sep 30, 2025 | -$282.73K | – |
| Q2 FY2025 | Jun 30, 2025 | $35.44K | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.35M | – |
| Q4 FY2024 | Dec 31, 2024 | -$752.14K | – |
| Q3 FY2024 | Sep 30, 2024 | -$392.37K | – |
| Q2 FY2024 | Jun 30, 2024 | -$661.65K | – |
| Q1 FY2024 | Mar 31, 2024 | -$560.52K | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.15M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.09M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.45M | – |
| Q1 FY2023 | Mar 31, 2023 | -$785.08K | – |
| Q4 FY2022 | Dec 31, 2022 | -$814.87K | – |
| Q3 FY2022 | Sep 30, 2022 | -$123.64K | – |
| Q2 FY2022 | Jun 30, 2022 | -$622.35K | – |
| Q1 FY2022 | Mar 31, 2022 | -$912.27K | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.04M | – |
| Q3 FY2021 | Sep 30, 2021 | -$475.15K | – |
| Q2 FY2021 | Jun 30, 2021 | -$896.70K | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.62M | – |
| Q4 FY2020 | Dec 31, 2020 | -$871.39K | – |
| Q3 FY2020 | Sep 30, 2020 | -$202.04K | – |
| Q2 FY2020 | Jun 30, 2020 | -$928.60K | – |
| Q1 FY2020 | Mar 31, 2020 | -$540.50K | – |
| Q4 FY2019 | Dec 31, 2019 | -$662.66K | – |
| Q3 FY2019 | Sep 30, 2019 | -$874.12K | – |
| Q2 FY2019 | Jun 30, 2019 | -$130.29K | – |
| Q1 FY2019 | Mar 31, 2019 | -$191.41K | – |
| Q4 FY2018 | Dec 31, 2018 | -$247.95K | – |
| Q3 FY2018 | Sep 30, 2018 | -$47.52K | -197.2% |
| Q2 FY2018 | Jun 30, 2018 | -$275 | – |
| Q1 FY2018 | Mar 31, 2018 | -$670 | – |
| Q4 FY2017 | Dec 31, 2017 | -$86.41K | -163.9% |
| Q3 FY2017 | Sep 30, 2017 | $48.88K | – |
| Q2 FY2017 | Jun 30, 2017 | -$260.42K | – |
| Q1 FY2017 | Mar 31, 2017 | -$64.59K | – |
| Q4 FY2016 | Dec 31, 2016 | $135.28K | – |
| Q3 FY2016 | Sep 30, 2016 | -$213.99K | – |
See a number that looks wrong?